Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2) and it is often used to treat patients with type 2 diabetes mellitus (T2DM) [1]. Here, SLC5A2 is linked to type 2 diabetes mellitus.